Bernstein analyst Nadine Sarwat lowered the firm’s price target on Ambev (ABEV) to $2.57 from $3.08 and keeps an Outperform rating on the shares. The normalization of U.S. alcohol consumption will remain the key theme of 2025, and the firm continues to believe a return to normal lies ahead.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEV: